Chief Exective Officer

Hiroshi Miyake

Hiroshi Miyake (Ph.D.) is a co-founder of Chordia Therapeutics and he has served as President and CEO and acted as a member of the board of directors since Chordia’s incorporation in November 2017. He has over 20 years of experience in drug discovery and his team has delivered programs to the clinical stage six times. Before the foundation of Chordia, he served as the site head of the oncology drug discovery unit at Takeda Pharmaceuticals. He earned his B.S. from Osaka University and his Ph.D. in Pharmacology from the University of Tokyo.

Chief Scientific Officer

Daisuke Morishita

Daisuke Morishita (Ph.D.) is the Chief Scientific Officer at Chordia Therapeutics and leads research initiatives developing cancer treatments that change lives. Prior to founding Chordia in November 2017, DAISUKE spent ten years working on oncology therapeutics at TAKEDA pharmaceutical company, focusing on cancer-related RNA networks. As the industry-academia collaboration representative at TAKEDA, DAISUKE led the CTX-177 drug discovery research as the representative of industry-academia collaboration programs in TAKEDA. Through the success of CTX-177 research, DAISUKE has been invited and held positions as an associate professor in Kyoto University to pursue a therapeutics strategy in cancer-related RNA network and an adjunct professor in Kumamoto University and Nagoya City University to produce next generation anti-cancer drugs. DAISUKE received Ph.D. in oncology from the University of Tokyo.

Chief Medical Officer

Yasushi Tanoue

Yasushi Tanoue has served as CMO since his appointment in September 2023.

Prior to joining Chordia, he worked in the departments of oncology clinical development and medical affairs in MSD, Merck Biopharma, and Eisai, and lead numerous projects successfully including clinical development (Phase 1-3), safety evaluation/management, regulatory approvals (Japan and Asian Countries), and launch strategies (new drug and biomarker).

Prior to joining the pharmaceutical industry, he worked as a physician and a researcher in gastrointestinal cancer and hepatitis at the University of Tokyo Hospital and its affiliated facilities. He was selected as one of the “Best Doctors in Japan” by Doctors.

He graduated from the Faculty of Medicine, the University of Tokyo (M.D.) and received Ph.D. at the Graduate of Medicine, the University of Tokyo.

Chief Administrative Officer

Yoshihiko Satoh

Yoshihiko Satoh, Ph.D. MBA has served as CAO and leads corporate management of Chordia. He contributed the licensing agreement with ONO Pharmaceuticals in 2020. Prior to joining Chordia in April 2018. He has over 10 years of experience in pharmacology on oncology therapeutic areas at Takeda and Astellas pharma

He received Ph.D. in Physiology from University of Kumamoto and Executive Master of Business Administration from NUCB Business School.

Chief Financial Officer

Kentaro Kume

Kentaro Kume brings over 20 years of experience with a multi-disciplinary background in corporate finance, M&A, procurement, transformation, and business strategy with Japan Financial Corporation, Cabinet office, Kearney and Takeda Pharmaceutical. Most recently, Kentaro engaged in the establishment and management of spinout companies to realize eco-system in iPark as the Head of Strategy & Operation APAC Center for External Innovation for Takeda Pharmaceutical. He received a Bachelor of Economics degree from Kyoto University and a Master of Management Technology degree from Tokyo University of Science.